Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.

Manish R. Patel,Gerald Steven Falchook,Judy Sing-Zan Wang,Esteban Rodrigo Imedio,Sanjeev Kumar,Pejvack Motlagh,Kowser Miah,Ganesh Mugundu,Suzanne F. Jones,David R. Spigel,Erika Paige Hamilton

Open-label, multicenter, phase I study to assess safety and tolerability of adavosertib plus durvalumab in patients with advanced solid tumors.

2019

Manish R. Patel
Gerald Steven Falchook
Judy Sing-Zan Wang
Esteban Rodrigo Imedio
Sanjeev Kumar
Pejvack Motlagh
Kowser Miah
Ganesh Mugundu
Suzanne F. Jones
David R. Spigel
Erika Paige Hamilton

2562Background: Adavosertib (AZD1775; A) is a highly selective inhibitor of WEE1. This Phase I study (NCT02617277) investigated a range of doses and schedules for oral A plus IV durvalumab (DV), a ...

Keywords:

Physical therapy
Durvalumab
Oncology
Medicine
Internal medicine
Tolerability
in patient
open label
highly selective
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations